单次静脉注射溶瘤性水疱性口炎病毒治疗复发难治性T细胞淋巴瘤的临床活性
一项1期临床试验评估单次静脉注射表达干扰素-β和碘化钠转运体的水疱性口炎病毒(VSV-IFNβ-NIS)在复发/难治性血液恶性肿瘤患者中的安全性和疗效。15例患者接受4个剂量水平治疗,未出现剂量限制性毒性;7例T细胞淋巴瘤中3例缓解,包括1例持续20个月的完全缓解。相关分析提示缓解可能源于直接溶瘤和免疫介导的肿瘤控制。
要点
- 单次静脉注射VSV-IFNβ-NIS在4个剂量水平均未出现剂量限制性毒性。
- 7例T细胞淋巴瘤中3例缓解,包括1例持续20个月的完全缓解。
- 完全缓解患者伴高水平血浆IFN-β、强中和抗体反应和肿瘤反应性T细胞增多。
核心结论
- VSV-IFNβ-NIS单药在T细胞淋巴瘤患者中有效,使经重度预处理患者获得持久疾病缓解。
- 相关分析提示缓解可能源于直接溶瘤性肿瘤破坏和免疫介导的肿瘤控制的共同作用。
研究设计与样本
- 1期临床试验,纳入复发/难治性血液恶性肿瘤患者,单次静脉注射VSV-IFNβ-NIS,设4个剂量水平。
- 15例患者接受VSV-IFNβ-NIS治疗;DL1至DL3(0.05、0.17和0.5×10^11 TCID50)各治疗3例,DL4(1.7×10^11 TCID50)治疗6例。
- 开展相关研究评估病毒血症、病毒排出、病毒复制和免疫反应。
主要发现
- DL1至DL4均未出现剂量限制性毒性。
- 7例T细胞淋巴瘤中3例缓解:DL2出现1例3个月部分缓解,DL4出现1例6个月部分缓解和1例持续20个月的完全缓解。
- 病毒血症在输注结束时达峰;血浆IFN-β在输注后4小时至48小时之间达峰。
- 完全缓解患者有强病毒复制,血浆游离DNA升高,IFN-β峰值达18 213 pg/mL,强抗VSV中和抗体反应,肿瘤反应性T细胞数量增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical success with intravenous (IV) oncolytic virotherapy (OV) has to-date been anecdotal. We conducted a phase 1 clinical trial of systemic OV and investigated the mechanisms of action in responding patients. A single IV dose of vesicular stomatitis virus (VSV) interferon-β (IFN-β) with sodium iodide symporter (NIS) was administered to patients with relapsed/refractory hematologic malignancies to determine safety and efficacy across 4 dose levels (DLs). Correlative studies were undertaken to evaluate viremia, virus shedding, virus replication, and immune responses. Fifteen patients received VSV-IFNβ-NIS. Three patients were treated at DL1 through DL3 (0.05, 0.17, and 0.5 × 1011 TCID50), and 6 were treated at DL4 (1.7 × 1011 TCID50) with no dose-limiting toxicities. Three of 7 patients with T-cell lymphoma (TCL) had responses: a 3-month partial response (PR) at DL2, a 6-month PR, and a complete response (CR) ongoing at 20 months at DL4. Viremia peaked at the end of infusion, g was detected. Plasma IFN-β, a biomarker of VSV-IFNβ-NIS replication, peaked between 4 hours and 48 hours after infusion. The patient with CR had robust viral replication with increased plasma cell-free DNA, high peak IFN-β of 18 213 pg/mL, a strong anti-VSV neutralizing antibody response, and increased numbers of tumor reactive T-cells. VSV-IFNβ-NIS as a single agent was effective in patients with TCL, resulting in durable disease remissions in heavily pretreated patients. Correlative analyses suggest that responses may be due to a combination of direct oncolytic tumor destruction and immune-mediated tumor control. This trial is registered at www.clinicaltrials.gov as #NCT03017820.
引用
- Cook J, Peng KW, Witzig TE, et al. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. Blood Adv. 2022. PMID: 35175355. doi:10.1182/bloodadvances.2021006631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。